NEW YORK (GenomeWeb News) – Molecular dermatology company HairDx, a subsidiary of PharmaGenoma, has launched a Belgian subsidiary to market its hair loss predictive test products in Europe, the company said today.
PharmaGenoma said that the HairDx Europe subsidiary will offer throughout Europe its genetic test for Androgenetic Alopecia, which the company said is the most common cause of hair loss in both men and women. The company noted that it has recently struck distribution agreements for the HairDX test in Italy and Japan.
Dirk Segers will serve as president of the HairDx Europe subsidiary, which will be based in Hasselt, Belgium.